Stories
Stories
Moderna Announces Promising Vaccine Trial Results
Stéphane Bancel (MBA 2000, AMP 170)
Photo by Richard Howard
Stéphane Bancel (MBA 2000, AMP 170)
Photo by Richard Howard
Moderna released promising news on the progress of their coronavirus vaccine this morning, noting that trials showed it to be 94.5% effective. “In this pandemic, what has been awful from a public health standpoint, an economic standpoint, is the worry people have to get so sick they have to go to the hospital—so sick they have to get to the ICU and have a high risk of dying,” Moderna CEO Stephane Bancel (MBA 2000) told The Washington Post. “If a [vaccine] could prevent 95 percent of people to not get disease, but to not get severe disease, that would be a game-changer: the impact on hospitals, the impact on people’s psyche and the impact on deaths.”
"These are obviously very exciting results," Dr. Anthony Fauci told CNN. "It's just as good as it gets—94.5% is truly outstanding."
A December HBS Alumni Bulletin article tracks Moderna’s path to this discovery, which began in January of this year, when it developed a treatment that went concept to clinical-trial-ready in a record-breaking 42 days. The article lays out just how radically fast the Moderna development timeline has been relative to previous vaccines—which have taken up to 13 years to come to fruition. Regarding the competitors in the race to develop a vaccine, though, Bancel makes a point in the December article that is increasingly relevant today as coronavirus cases spike nationwide: “We’re not racing against each other,” he told the Bulletin. “We’re racing the virus.”
Post a Comment
Related Stories
-
- 26 Oct 2020
- HBS Alumni News
A Social Impact Roadmap; Arts Leadership in a Pandemic; Amplifying Hispanic Contributions
Re: Ronald Cohen (MBA 1969); Cissy Chen (MBA 2019); Julie Mulcahy (GMP 24); Karen Hung (MBA 1998); Melanie Maddux (MBA 2004); Steven Schaumberger (MBA 1988); Vikram Gandhi (Senior Lecturer of Business Administration); Rebecca M. Henderson (John and Natty McArthur University Professor); George Serafeim (Charles M. Williams Professor of Business Administration); By: Margie Kelley -
- 22 Oct 2020
- HBS News
A Q+A with Dash Camp Founder Tabitha Salomon (MBA 2014)
Re: Tabitha Salomon (MBA 2014) -
- 14 Oct 2020
- HBS Alumni News
Sewn with Love
Re: Kikka Hanazawa (MBA 2002); By: Maureen Harmon -
- 24 Sep 2020
- HBS Alumni Bulletin
The Race for a Vaccine
Re: Stefan Bancel (MBA 2000); Kate Bingham (MBA 1991); Gary P. Pisano (Harry E. Figgie, Jr. Professor of Business Administration Senior Associate Dean for Faculty Development); By: April White
Stories Featuring Stefan Bancel
-
- 24 Sep 2020
- HBS Alumni Bulletin
The Race for a Vaccine
Re: Stefan Bancel (MBA 2000); Kate Bingham (MBA 1991); Gary P. Pisano (Harry E. Figgie, Jr. Professor of Business Administration Senior Associate Dean for Faculty Development); By: April White -
- 04 Jun 2020
- HBS Health Care Initiative
Moderna – Pivoting Research and Operations During a Pandemic
Re: Stefan Bancel (MBA 2000); Srikant M. Datar (Arthur Lowes Dickinson Professor of Business Administration Senior Associate Dean for University Affairs) -
- 04 Jun 2020
- HBS Health Care Initiative
Perspectives in Health: Moderna - Pivoting Research and Ops During a Pandemic
Re: Stefan Bancel (MBA 2000); Srikant M. Datar (Arthur Lowes Dickinson Professor of Business Administration Senior Associate Dean for University Affairs)
